Research Highlight Published: 01 June 2006 Sevelamer for treating hyperphosphatemia in pediatric CKD patients Rachael Williams Nature Clinical Practice Nephrology 2, 296 (2006) Cite this article ...

In this video, Kevin Martin, MD, discusses treatment options available to patients with hyperphosphatemia.

The trial demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate ...

The global hyperphosphatemia treatment market grew from $3.57 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the ...

Increasing product launches and approval of novel drugs in key regions around the globe are expected to fuel the global hyperphosphatemia drugs market growth in the near future. For instance, in 2016, ...

About Hyperphosphatemia Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD).

In this video, Kevin Martin, MD, discusses new and emerging technologies in the field of hyperphosphatemia.

Among the 184 survivors of 24-hour CRRT, hyperphosphatemia was associated with a significant 2.2 times and 2.6 times increased risk of death at 28 days and 90 days, respectively.

Key Takeaways from the Market Study The global hyperphosphatemia market is expected to reach US$ 20.24 billion by 2033, growing at a CAGR of 4.8%. Iron-based phosphate binder is expected to grab 20% ...

Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan.